An adaptive quitting study changed its design: was the change planned?

Identify the feature allowed to change

FDA’s adaptive-design guidance describes prospectively planned modifications based on accumulating trial information. Examples concern different aspects of design, so adaptive is not one procedure. The guidance is used here for general research terminology, without making a drug recommendation or claiming that a quitting product has regulatory approval.

Locate the actual allowed change, such as sample size, allocation, or another specified feature. Keep it attached to the study’s outcome question. A report that changed a calendar detail for an administrative reason is not necessarily describing the same design concept. Read what the authors meant before upgrading every revision into an adaptive-method claim.

US Food and Drug Administration: Adaptive Designs for Clinical Trials of Drugs and Biologics (November2019)

Make an original rule-and-action timeline

Imagine a fictional protocol allowing a particular enrollment adjustment after a scheduled review of specified data. On a timeline, mark rule documented, review occurred, decision made, and change implemented. Write what evidence the decision was permitted to use. These are invented administrative stages, not a real trial or an endorsement of the rule.

If the final report says the adjustment occurred, look for whether it followed that documented rule. If no change occurred, the plan may still have allowed it; permission to adapt and a realized adaptation are different facts. Do not rewrite the protocol as though it predicted the exact decision that would eventually be made.

Read who had access to interim information

A planned rule does not resolve every question about trial conduct. Look for the report’s description of who reviewed accumulating information, how decisions were communicated, and how the final analysis accounted for the design. Keep unclear points as questions rather than inventing a monitoring committee or assuming everyone knew the same results.

Comparative interim information can affect decisions, so the timing of the plan matters. An analysis document written after such information became available is not evidence of an earlier rule merely because the later wording is detailed. Conversely, a documented explanation of an unplanned change should be read rather than automatically treated as misconduct.

Separate design flexibility from the finding

Your summary can name the planned adaptation, what actually happened, and the reported effect with its own limitations. Adaptive does not mean that the intervention adapts to each user, that participants chose their own treatment, or that the study must have succeeded. Those claims need separate evidence and precise definitions.

This guide does not assess a named adaptive trial or select a statistical procedure. A qualified professional can help interpret evidence relevant to care. Your personal decision to revise a coping activity is ordinary planning, not an adaptive clinical trial. The useful research output is a traceable timeline showing what was planned, what was observed, and which question about inference remains open.